ADULT WOMEN WITH PAPILLARY THYROID CANCER

PREZENTĂRI DE CAZ

Assoc. Prof. Adina Ghemigian1,2, MD, PhD, Assist. Prof. Mara Carsote1,2, MD, PhD, Lecturer Ana Valea3,4, MD, PhD, Assoc. Prof. Ancuta Augustina Gheorghisan-Galteanu1,2, MD, PhD, Lecturer Rucsandra Danculescu-Miulescu5,6, MD, PhD, Assoc. Prof. Diana Loreta Paun1,2, MD, PhD

1Department of Gynaecology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
2Constantin Ion Parhon National Institute of Endocrinology, Bucharest, Romania
3Department of Endocrinology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
4Department of Endocrinology, Clinical County Hospital, Cluj-Napoca, Romania
5Nicolae Paulescu National Institute, Bucharest, Romania

ABSTRACT

Differentiated thyroid cancer of papillary type have an increasing incidence on women of reproductive age but also in menopause, possible related to new triggers that act as endocrine disruptors which are more or less described until this moment or possible related to the increased accessibility to thyroid ultrasound. The incidence of non-medullary thyroid cancer in women is 3 times higher than in males so the influence of estrogens seems rational. Yet, some meta-analyses did not confirm a direct link with estrogens exposure during reproductive years. Thyroid cancer is also diagnosed in menopause which is a low estrogens status thus other risk factors should be taken into consideration; among these obesity and smoking are frequently incriminated. We aim to introduce a two cases series of adult females with differentiated thyroid carcinoma which was diagnosed from an initial routine ultrasound.

Keywords: thyroid cancer, ultrasound, thyroid nodule

INTRODUCTION

Differentiated thyroid cancer of papillary or follicular type have an increasing incidence on women of reproductive age but also in menopause, possible related to new triggers that act as endocrine disruptors which are more or less described until this moment or possible related to the increased accessibility to thyroid ultrasound (1,2,3). The incidence of non-medullary thyroid cancer in women is 3 times higher than in males so the influence of estrogens seems rational (4). Population based studies showed that the risk increases with the age of first menstruation while for women in menopause 2 additional risk factors are potentially involved: surgical menopause and the age of menopause earlier than 55 years (4). Opposite, breastfeeding, oral contraceptives and menopausal hormone therapy might decrease the risk of follicular cells-related cancer (4). Among the two types of differentiated thyroid cancer, most correlations with estrogens status involve papillary rather than follicular type (5). Yet, some meta-analyses did not confirm a direct link with estrogen exposure during reproductive years (5). Recently, a study showed that risk of cancer (including thyroid cancer) is higher in infertile women versus fertile subjects (in years following the infertility evaluation) (6). Thyroid cancer is also diagnosed in menopause which is a low estrogens status thus other risk factors should be taken into consideration; among these obesity and smoking are frequently incriminated (7). On the other hand, the women diagnosed and treated for thyroid cancer may have a higher risk of abnormal parameters regarding reproductive years (8).

AIM

We aim to introduce a two cases series of adult females with differentiated thyroid carcinoma which was diagnosed from an initial routine ultrasound.

METHOD

This is a case report. Ultrasound feature and thyroid profile is introduced.
CASE PRESENTATION 1

This is a 76 year old non-smoking female resident in iodine sufficient area. She is known for the last three years with ultrasound-detected thyroid nodule with suspect features for thyroid cancer. Thyroidectomy was recommended at that time but the patient refused it. Currently, the thyroid ultrasound shows a right lobe of 3.3 by 3.2 by 4.3 cm, which is entirely displayed by a nodular conglomerate with hypechoic, inhomogeneous pattern, containing several infiltrative images into the lobe and anterior capsule while posterior contour is shaded. The nodule is mobile during deglutition and it has very large diameters: 4.3 by 3.4 by 3.3 cm (TI-RADS 4C) (Fig. 1).

The isthmus also associates a nodular conglomerate with displays the normal structure, of 1.3 by 0.88 by 1.8 cm (Fig. 2).

The left lobe has 4-5 micronodules of maximum 0.52 cm. No local lymph nodes were detected. TSH (Thyroid Stimulating Hormone) is normal, so is blood calcitonin, and anti-thyroid antibodies. Despite the high malignancy risk based on fine needle aspiration pointing a papillary carcinoma, the patient still refused thyroid removal.

Case presentation 2

This is a 48-year old non-smoking female, resident for non-endemic area, who had a routine ultrasound done at the level of thyroid. A suspect nodule of 3 cm is identified. On admission, the multinodular goitre is also clinically detected with normal thyroid function confirmed by blood TSH. The ultrasound reveals: the right thyroid lobe has 1.49 by 1.59 by 4.73 cm, the isthmus has 0.84 cm, the left lobe has 2.5 by 3.03 by 5.23 cm with inhomogeneous, hypechoic pattern, polinodular aspect: right lobe has a nodule with some small area on necrosis insight of 1.33 by 0.88 by 0.93 cm, left lobe has another several nodules which are poorly shaped forming a conglomerate of 3 by 2.5 by 2.27 cm, and another nodule of 0.89 by 0.54 by 0.73 cm; the isthmus has a micronodule of 0.6 by 0.4 by 0.6 cm, and a macrolcalcification of 0.22 by 0.13 cm. No latero-cervical adenopathy is identified (Fig. 3).
Fine needle aspiration showed Hurtle cells with potential follicular proliferation. Total thyroidectomy is performed without surgical complications. The pathologic report confirmed a papillary carcinoma of follicular type. Further radioiodine I\textsuperscript{131} was added and life suppressive levothyroxine therapy was initiated.

**DISCUSSION**

The first case has indication of thyroidectomy because of ultrasound aspects. The fine needle aspiration is useful in addition to ultrasound to point the malignancy risk but the patient was not compliant. Highly introduced TI-RADS classification combines composition, margins, hypoechoic foci, shape, and echogenity to a scoring system in order to indicate the risk of malignancy and further approach like fine needle aspiration or thyroidectomy (9,10). TI-RADS 4 means a risk of malignancy of 50-85% (9,10). The second cases introduce Hurtle cells connected issues. The cancer with this type of cells has a more aggressive profile and their identification starts from cytological report (this particular aspect was study including in Romanian population) (10,11,12). However, in our second case their post-operative histological confirmation was not done.

**CONCLUSION**

Thyroid ultrasound remains the best tool for high risk nodules in both pre- and post-menopausal women if direct information based on fine needle aspiration or pathological exam is not done.
REFERENCES

1. Shi, LL, DeSantis, C, Jemal, A, Chen, AY. Changes in thyroid cancer incidence, post-2009 American Thyroid Association guidelines. Laryngoscope 2017, 127(10), pp. 2437-2441.

2. Liao S, Shindo M. Management of well-differentiated thyroid cancer. Otolarngol Clin North Am 2012, 45(5), pp. 1163-79.

3. Pacini F, Castagna MG, Brill L, Jost L. ESMO Guidelines Working Group. Differentiated thyroid cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008, 19 Suppl 2:i99-101. doi: 10.1093/annonc/mdn115.

4. Cordina-Duverger E, Leux C, Neri M, Tcheandjieu C, Guizard AV, Schwart C, Truong T, Guénel P. Hormonal and reproductive risk factors of papillary thyroid cancer: A population-based case-control study in France. Cancer Epidemiol 2017, 48, pp. 78-84.

5. Wang P, Lv L, Qi F, Qiu, F. Increased risk of papillary thyroid cancer related to hormonal factors in women. Tumour Biol 2015, 36(7), pp. 5127-32.

6. Murugappan G, Li S, Lathi RB, Baker VL, Eisenberg ML. Risk of cancer in infertile women: analysis of us claims data. Hum Reprod. 2019 Mar 13. pii: dez018. doi: 10.1093/humrep/dez018. (Epub ahead of print)

7. Kitahara CM, Sosa JA. The changing incidence of thyroid cancer. Nat Rev Endocrinol 2016, 12(11), pp. 646-653.

8. Blackburn BE, Ganz PA, Rowe K, Snyder J, Wan Y, Deshmukh V, Newman M, Fraser A, Smith K, Herget K, Kim J, Kirchhoff AC, Porucznik C, Hanson H, Abraham D, Monroe M, Hashibe M. Reproductive and gynecological complication risks among thyroid cancer survivors. J Cancer Surviv 2018, 12(5), pp. 702-711.

9. http://tiradscalculator.com/

10. http://webcir.org/revistavirtual/articulos/noviembre14/argentina/tirads_classification.pdf

11. Poiana C, Carso M, Ardeleanu C, Terzea D, Avramescu ET, Neamtu MC, Miulescu RD. The value of the immunohistochemistry in a case of gastric neuroendocrine tumor and thyroidmetastasis. Rom J Morphol Embryol 2011, 52(1), pp. 187-92.

12. Stanciu M, Zaharie IS, Bera LG, Cioca G. Correlations between the presence of Hurthle cells and cyt morphological features of fine-needle aspiration biopsy in thyroid nodules. Acta Endo 2016, (Buc) 12(4), pp. 485-490.

13. Grani G, Lamartina L, Durante C, Filetti S, Cooper DS. Follicular thyroid cancer and Hürthle cell carcinoma: challenges in diagnosis, treatment, and clinical management. Lancet Diabetes Endocrinol 2018, 6(6), pp. 500-514.